SCHEMBL651482

SCHEMBL651482

O=C(O)c1cc2n[nH]c(NC(=O)c3ccccc3[N+](=O)[O-])c2o1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
GAA P10253 2/20 0.46
HTT P42858 1/20 0.46
NCOA1 Q15788 1/20 0.46
NCOA3 Q9Y6Q9 1/20 0.46
ALDH1A1 P00352 5/20 0.44
GPR35 Q9HC97 1/20 0.44
ABCG2 Q9UNQ0 2/20 0.43
HPGD P15428 1/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL652871 0.83 ALPL (0.43) KMT2ANPC1RAB9ASMN1; SMN2GAA
SCHEMBL651209 0.81 CYP1A2 (0.46) MEN1KMT2ANPC1RAB9ACYP1A2
SCHEMBL653043 0.80 MEN1 (0.52) MEN1KMT2ANPC1RAB9ACYP1A2
SCHEMBL653933 0.69 MEN1 (0.43) MEN1KMT2ANPC1RAB9ACYP1A2
SCHEMBL7717663 0.69 ALDH1A1 (0.66) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL995085 0.68 GAA (0.77) MEN1KMT2ARAB9ACYP1A2CYP3A4
SCHEMBL4088694 0.68 HCAR2 (0.33) MEN1KMT2AGPR35MAPT
SCHEMBL7722700 0.67 ALDH1A1 (0.68) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL2801162 0.67 CYP1A2 (0.53) MEN1KMT2ANPC1RAB9ACYP1A2
SCHEMBL653044 0.67 CYP1A2 (0.50) MEN1KMT2ANPC1RAB9ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119641-B2 1H-furo[3,2-C]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-21 US disclosed
EP-2051981-B1 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2010-08-25 EP disclosed
US-20090239924-A1 1H-FURO[3,2-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-09-24 US disclosed
EP-2051981-A1 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2009-04-29 EP disclosed
WO-2007138017-A1 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239924-A1 1H-FURO[3,2-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS IGF1R, CDK1, CDK15 MEN1 1095/4885KMT2A 2181/4885NPC1 1674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.